Roche has agreed a discount on obinutuzumab that has led Nice to recommend it is made available on the NHS A life-prolonging leukaemia drug rejected by the health advisory body is to be made available on the NHS after the manufacturer agreed to lower the price. The National Institute for Health and Care Excellence ruled in October that obinutuzumab should not be made widely available for chronic lymphocytic leukaemia patients because of gaps in Roche’s economic proposal.
Are you up for a challenge?
